In a specific sub-group of patients with Ohtahara syndrome, the condition is driven by an identifiable and correctable metabolic deficiency — either pyridoxine (vitamin B6) deficiency or biotinidase deficiency. Identifying this aetiology has direct therapeutic implications and is associated with relatively more favourable outcomes compared with other presentations of this syndrome.
This protocol applies when Ohtahara syndrome occurs in the setting of underlying pyridoxine (vitamin B6) deficiency or biotinidase deficiency. Establishing the metabolic cause in these patients is a critical step, as it defines the treatment pathway for this specific sub-group.
Patients with Ohtahara syndrome in this context have been reported to do relatively well after the underlying deficiency is identified and addressed.
The protocol focuses on correction of the underlying metabolic disorder — targeting the deficiency itself rather than the seizure phenotype in isolation. The complete structured regimen, including clinical decision points, is available via the link below.
The correction of underlying metabolic disorders may lead to more favorable outcomes.
In particular, patients with Ohtahara syndrome have been reported to do relatively well after the correction of underlying pyridoxine deficiencies or biotinidase deficiencies.
View source ↗